Literature DB >> 12271373

Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Ursula Schlötzer-Schrehardt1, Arne Viestenz, Gottfried O H Naumann, Horst Laqua, S Michels, Ursula Schmidt-Erfurth.   

Abstract

PURPOSE: To determine the effects of photodynamic therapy (PDT) on choroidal and retinal structures of human eyes.
METHODS: One eye from each of three patients with large malignant melanomas of the uvea destined for enucleation received PDT using verteporfin according to the approved treatment recommendations for patients with age-related macular degeneration. Two laser spots and two light doses (50 J/cm(2) and 100 J/cm(2)) were applied in unaffected chorioretinal areas. The effects of PDT were assessed by fluorescein and indocyanine-green angiography. The eyes were enucleated 1 week later, fixed in buffered paraformaldehyde/glutaraldehyde solution, bisected along the laser spots, and processed for light and electron microscopy.
RESULTS: In agreement with the clinical angiographic findings of hypofluorescence, a rather selective occlusion of the choriocapillary layer was observed in the 50-J/cm(2) PDT areas, whereas the 100-J/cm(2) PDT areas additionally revealed closure of deeper choroidal vessels and focal alterations of the retinal pigment epithelium. The overlying neurosensory retina, including photoreceptors and retinal capillaries, was well preserved in all PDT areas. Electron microscopy showed that alterations of the choriocapillary endothelium comprised swelling, shrinkage and fragmentation of endothelial cells, detachment from their basement membrane up to complete degeneration of the endothelial lining, leading to platelet aggregation, degranulation, and thrombus formation. Complete occlusion of capillary lumina by fibrin, thrombocytes, and cellular debris was observed. Remaining intact endothelial cells appeared to be reorganized into novel smaller vascular channels within occluded lumina.
CONCLUSIONS: PDT with verteporfin at a dosage used clinically induces selective occlusion of the physiological choriocapillaris without affecting deeper choroidal, retinal, and optic nerve vessels or the overlying retinal pigment epithelium and neurosensory retina. The main mechanism of action appears to be vascular thrombosis induced by cytotoxic damage of endothelial cells and platelet activation. An increase in light dose enhances the occlusive effect with thrombosis within deeper choroidal layers and damage to the retinal pigment epithelium. However, photoreceptors remained intact at all light doses used.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12271373     DOI: 10.1007/s00417-002-0517-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  75 in total

1.  Low-fluence photodynamic therapy combinations in the treatment of exudative age-related macular degeneration.

Authors:  Taylan Ozturk; Hakan Oner; Ali Osman Saatci; Suleyman Kaynak
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

2.  Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.

Authors:  Yildirim Bayezit Sakalar; Ugur Keklikci; Kaan Unlu; Mehmet Fuat Alakus; Ismail Hamdi Kara
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

3.  Early OCT changes of neuroretinal foveal thickness after first versus repeated PDT in AMD.

Authors:  Gennady Landa; Amir Bukelman; Haya Katz; Ayala Pollack
Journal:  Int Ophthalmol       Date:  2007-12-20       Impact factor: 2.031

4.  Dynamics of retinal function after multiple photodynamic therapies in age-related macular degeneration: a report of cases.

Authors:  Beatrix Feigl; Brian Brown; Jan Lovie-Kitchin; Lawrence Lee
Journal:  Doc Ophthalmol       Date:  2006-03-06       Impact factor: 2.379

5.  Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  R Uetani; Y Ito; K Oiwa; K Ishikawa; H Terasaki
Journal:  Eye (Lond)       Date:  2012-05       Impact factor: 3.775

6.  Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms.

Authors:  Kazuhiro Oiwa; Keiko Kataoka; Ruka Maruko; Shinji Ueno; Yasuki Ito; Hiroko Terasaki
Journal:  Jpn J Ophthalmol       Date:  2017-02-02       Impact factor: 2.447

7.  Concentric retinal pigment epithelium atrophy after a single photodynamic therapy.

Authors:  Joachim Wachtlin; Tim Behme; Heinrich Heimann; Ulrich Kellner; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-05-07       Impact factor: 3.117

8.  [Photodynamic therapy with verteporfin for uveal melanoma].

Authors:  J Wachtlin; N E Bechrakis; M H Foerster
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

Review 9.  Spotlight on verteporfin in subfoveal choroidal neovascularisation.

Authors:  Susan J Keam; Lesley J Scott; Monique P Curran
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

10.  Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.

Authors:  Eric Chen; David M Brown; Tien P Wong; Matthew S Benz; Eric Kegley; Joel Cox; Richard H Fish; Rosa Y Kim
Journal:  Clin Ophthalmol       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.